Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Negative clinical history for varicella, herpes zoster, measles, mumps, and rubella~Exclusion Criteria:~* Received any measles, mumps, rubella, or varicella vaccine at any time prior to the study, or is anticipated to receive any of these vaccines outside the study~* Any congenital or acquired immune deficiency, neoplastic disease, or depressed immunity~* Received systemic immunomodulatory steroids within 3 months prior to entering the study or is expected to receive them during the course of the study~* History of allergy or anaphylactic reaction to neomycin, gelatin, sorbitol, egg proteins, chicken proteins, or any component of VARIVAX® or M-M-R II®~* Has any blood dyscrasias, leukemia, lymphoma, or other malignant neoplasm affecting the bone marrow or lymphatic systems~* Received salicylates within 14 days prior to study vaccination~* Exposed to varicella, herpes zoster, measles, mumps, or rubella in the 4 weeks prior to study vaccination~* Received immune globulin, a blood transfusion, or blood-derived products within 5 months prior to study vaccination~* History of seizure disorder, including febrile seizure~* Fever illness (\>=102.2 °F \[39.0 °C\] within 72 hours prior to study vaccination~* History of thrombocytopenia~* Born to a human immunodeficiency virus (HIV)-infected mother~* Has a diagnosis of active untreated tuberculosis~* Participated in any other clinical trial (other than a surveillance study) within 30 days prior to study enrollment.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 23 Months
- Healthy Volunteers: t

Study Arms:
- VARIVAX® PE34 Process + Measles, Mumps, Rubella (M-M-R) II® (Type: EXPERIMENTAL): VARIVAX® Passage Extension (PE34) Process vaccine 0.5 mL administered in the left arm or thigh and M-M-R II® vaccine 0.5 mL administered in the right arm or thigh by subcutaneous injection on Day 1 and Day 91
- VARIVAX® 2016 Commercial Process + M-M-R II® (Type: ACTIVE_COMPARATOR): VARIVAX® 2016 Commercial Process vaccine 0.5 mL administered in the left arm or thigh and M-M-R II® vaccine 0.5 mL administered in the right arm or thigh by subcutaneous injection on Day 1 and Day 91

Based on this trial design, predict the completion outcome and termination type (if applicable).